TY - JOUR
T1 - ZNF469 frequently mutated in the brittle cornea syndrome (BCS) is a single exon gene possibly regulating the expression of several extracellular matrix components.
AU - Rohrbach, M
AU - Spencer, HL
AU - Porter, LF
AU - Burkitt Wright, Emma
AU - Burkitt-Wright, EM
AU - Bürer, C
AU - Janecke, A
AU - Bakshi, M
AU - Sillence, D
AU - Al-Hussain, H
AU - Baumgartner, M
AU - Steinmann, B
AU - Black, GC
AU - Manson, FD
AU - Giunta, C
PY - 2013/7
Y1 - 2013/7
N2 - Brittle cornea syndrome (BCS; MIM 229200) is an autosomal recessive generalized connective tissue disorder caused by mutations in ZNF469 and PRDM5. It is characterized by extreme thinning and fragility of the cornea that may rupture in the absence of significant trauma leading to blindness. Keratoconus or keratoglobus, high myopia, blue sclerae, hyperelasticity of the skin without excessive fragility, and hypermobility of the small joints are additional features of BCS. Transcriptional regulation of extracellular matrix components, particularly of fibrillar collagens, by PRDM5 and ZNF469 suggests that they might be part of the same pathway, the disruption of which is likely to cause the features of BCS. In the present study, we have performed molecular analysis of a cohort of 23 BCS affected patients on both ZNF469 and PRDM5, including those who were clinically reported previously [1]; the clinical description of three additional patients is reported in detail. We identified either homozygous or compound heterozygous mutations in ZNF469 in 18 patients while, 4 were found to be homozygous for PRDM5 mutations. In one single patient a mutation in neither ZNF469 nor PRDM5 was identified. Furthermore, we report the 12 novel ZNF469 variants identified in our patient cohort, and show evidence that ZNF469 is a single exon rather than a two exon gene. © 2013 Elsevier Inc.
AB - Brittle cornea syndrome (BCS; MIM 229200) is an autosomal recessive generalized connective tissue disorder caused by mutations in ZNF469 and PRDM5. It is characterized by extreme thinning and fragility of the cornea that may rupture in the absence of significant trauma leading to blindness. Keratoconus or keratoglobus, high myopia, blue sclerae, hyperelasticity of the skin without excessive fragility, and hypermobility of the small joints are additional features of BCS. Transcriptional regulation of extracellular matrix components, particularly of fibrillar collagens, by PRDM5 and ZNF469 suggests that they might be part of the same pathway, the disruption of which is likely to cause the features of BCS. In the present study, we have performed molecular analysis of a cohort of 23 BCS affected patients on both ZNF469 and PRDM5, including those who were clinically reported previously [1]; the clinical description of three additional patients is reported in detail. We identified either homozygous or compound heterozygous mutations in ZNF469 in 18 patients while, 4 were found to be homozygous for PRDM5 mutations. In one single patient a mutation in neither ZNF469 nor PRDM5 was identified. Furthermore, we report the 12 novel ZNF469 variants identified in our patient cohort, and show evidence that ZNF469 is a single exon rather than a two exon gene. © 2013 Elsevier Inc.
KW - Brittle cornea
KW - Genetic heterogeneity
KW - Keratoconus
KW - Keratoglobus
KW - PRDM5 and ZNF469
KW - Single exon gene
U2 - 10.1016/j.ymgme.2013.04.014
DO - 10.1016/j.ymgme.2013.04.014
M3 - Article
C2 - 23680354
SN - 1096-7192
VL - 109
SP - 289
EP - 295
JO - Molecular genetics and metabolism
JF - Molecular genetics and metabolism
IS - 3
ER -